{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:12:28Z","timestamp":1775632348725,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["annalsthoracicsurgery.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Annals of Thoracic Surgery"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.athoracsur.2025.01.013","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T08:41:21Z","timestamp":1738226481000},"page":"167-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft Surgery"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3435-8487","authenticated-orcid":false,"given":"Shubh K.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam S.","family":"Badross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitish K.","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Moroney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack H.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed M.","family":"Ali Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayyab S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlys L.","family":"Koschinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwee","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-8533","authenticated-orcid":false,"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.athoracsur.2025.01.013_bib1","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib2","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.3390\/ijerph20186721","article-title":"Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives","volume":"20","author":"Vinci","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0021-9150(01)00423-3","article-title":"Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G\/G genotype in CAD patients","volume":"158","author":"Szalai","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib4","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib5","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib6","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031322","article-title":"Impact of high lipoprotein(a) on long-term survival following coronary artery bypass grafting","volume":"13","author":"Yuan","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.atherosclerosis.2014.05.944","article-title":"Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting","volume":"235","author":"Ezhov","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.atherosclerosissup.2017.05.011","article-title":"Association of lipoprotein(a) level with short-and long-term outcomes after CABG: the role of lipoprotein apheresis","volume":"30","author":"Ezhov","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.amjcard.2019.10.037","article-title":"Impact of lipoprotein(a) on long-term (mean 6.2 years) outcomes in patients with three-vessel coronary artery disease","volume":"125","author":"Xu","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0002-9343(00)00652-5","article-title":"Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men","volume":"110","author":"Seed","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjcard.2020.08.049","article-title":"Usefulness of lipoprotein (a) for predicting outcomes after percutaneous coronary intervention for stable angina pectoris in patients on hemodialysis","volume":"136","author":"Hishikari","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib15","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/01.CIR.77.6.1238","article-title":"Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients","volume":"77","author":"Hoff","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.atherosclerosissup.2017.05.009","article-title":"Rationale and design of MultiSELECt: a European multicenter study on the effect of lipoprotein(a) elimination by lipoprotein apheresis on cardiovascular outcomes","volume":"30","author":"Hohenstein","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2018.07.010","article-title":"Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: pooled analysis of eight ODYSSEY phase 3 trials","volume":"277","author":"Kereiakes","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-5223(03)00365-9","article-title":"Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery","volume":"126","author":"Pokrovsky","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.athoracsur.2025.01.013_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11789-019-00096-2","article-title":"Lipoprotein(a)-antisense therapy","volume":"14","author":"Vogt","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib21","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib22","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/biom12010026","article-title":"Lipoprotein(a)-the crossroads of atherosclerosis, atherothrombosis and inflammation","volume":"12","author":"Ugov\u0161ek","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.freeradbiomed.2019.10.011","article-title":"Role of reactive oxygen species in atherosclerosis: lessons from murine genetic models","volume":"149","author":"Negre-Salvayre","year":"2020","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3491764","article-title":"Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule","volume":"2020","author":"Jawi","year":"2020","journal-title":"J Lipids"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib26","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib27","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"203","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1130162","article-title":"Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages","volume":"10","author":"Lorey","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib30","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.hlc.2013.01.012","article-title":"NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis","volume":"22","author":"Zheng","year":"2013","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib31","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.hlc.2014.04.256","article-title":"Overexpression of caspase-1 in aorta of patients with coronary atherosclerosis","volume":"23","author":"Zheng","year":"2014","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrg.2016.160","article-title":"Genetics of coronary artery disease: discovery, biology and clinical translation","volume":"18","author":"Khera","year":"2017","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib33","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib34","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1093\/eurheartj\/ehae191","article-title":"Eight reasons why lipoprotein(a) should be measured in everyone at least once in a lifetime","volume":"45","author":"Arsenault","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib35","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib36","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/0002-9149(94)90459-6","article-title":"Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting","volume":"74","author":"Eritsland","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib37","doi-asserted-by":"crossref","DOI":"10.23736\/S2724-5683.24.06534-7","article-title":"Association between lipoprotein levels and outcomes after coronary artery bypass grafting surgery: a systematic review and meta-analysis","author":"Cancelli","year":"2024","journal-title":"Minerva Cardiol Angiol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib38","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa1716026","article-title":"Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery","volume":"378","author":"Gaudino","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.atherosclerosis.2011.05.039","article-title":"Increased lipoprotein(a) is associated with polyvascular disease in patients undergoing coronary artery bypass graft","volume":"219","author":"Song","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib40","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/STROKEAHA.110.595546","article-title":"Biomarkers of asymptomatic carotid stenosis in patients undergoing coronary artery bypass grafting","volume":"42","author":"Kim","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib41","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib42","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib43","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib44","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib45","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib46","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib47","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib48","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib51","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib53","first-page":"1408","article-title":"Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial","volume":"44","author":"Schwartz","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib54","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib55","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib56","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib57","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athoracsur.2025.01.013_bib58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","article-title":"Lipoprotein(a) and ethnicities","volume":"349","author":"Mehta","year":"2022","journal-title":"Atherosclerosis"}],"container-title":["The Annals of Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497525000803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497525000803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T09:56:43Z","timestamp":1750672603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497525000803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0003497525000803"],"URL":"https:\/\/doi.org\/10.1016\/j.athoracsur.2025.01.013","relation":{},"ISSN":["0003-4975"],"issn-type":[{"value":"0003-4975","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft Surgery","name":"articletitle","label":"Article Title"},{"value":"The Annals of Thoracic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athoracsur.2025.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The Society of Thoracic Surgeons.","name":"copyright","label":"Copyright"}]}}